Quantifying CDK inhibitor selectivity in live cells

[1]  M B Robers,et al.  Quantifying Target Occupancy of Small Molecules Within Living Cells. , 2020, Annual review of biochemistry.

[2]  S. Goueli,et al.  A homogeneous bioluminescent immunoassay to probe cellular signaling pathway regulation , 2020, Communications Biology.

[3]  David J. Fallon,et al.  A Photoaffinity Displacement Assay and Probes to Study the Cyclin-Dependent Kinase Family. , 2019, Angewandte Chemie.

[4]  Concha Sánchez-Martínez,et al.  Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015-2019). , 2019, Bioorganic & medicinal chemistry letters.

[5]  A. Lin,et al.  Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials , 2019, Science Translational Medicine.

[6]  Sarah A. Boswell,et al.  Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity. , 2019, Cell chemical biology.

[7]  David A. Orlando,et al.  Discovery and characterization of SY-1365, a selective, covalent inhibitor of CDK7. , 2019, Cancer research.

[8]  Jared L. Johnson,et al.  Discovery of Covalent CDK14 Inhibitors with Pan-TAIRE Family Specificity. , 2019, Cell chemical biology.

[9]  Haopeng Sun,et al.  CDK8 as a therapeutic target for cancers and recent developments in discovery of CDK8 inhibitors. , 2019, European journal of medicinal chemistry.

[10]  W. Tilley,et al.  Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update. , 2018, Journal of medicinal chemistry.

[11]  K. Comess,et al.  Quantitative, Real-Time Measurements of Intracellular Target Engagement Using Energy Transfer. , 2018, Methods in molecular biology.

[12]  S. Knapp,et al.  Binding Kinetics Survey of the Drugged Kinome. , 2018, Journal of the American Chemical Society.

[13]  V. Kryštof,et al.  How Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases? , 2018, Journal of medicinal chemistry.

[14]  M. Mcdougall,et al.  Quantitative Live-Cell Kinetic Degradation and Mechanistic Profiling of PROTAC Mode of Action. , 2018, ACS chemical biology.

[15]  J. Fins.  Family Portrait , 2018, Narrative inquiry in bioethics.

[16]  N. Gray,et al.  Kinase inhibitors: the road ahead , 2018, Nature Reviews Drug Discovery.

[17]  Simak Ali,et al.  ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment , 2018, Molecular Cancer Therapeutics.

[18]  Robert A Copeland,et al.  The Elements of Translational Chemical Biology. , 2017, Cell chemical biology.

[19]  T. Willson,et al.  Quantitative, Wide-Spectrum Kinase Profiling in Live Cells for Assessing the Effect of Cellular ATP on Target Engagement , 2017, Cell chemical biology.

[20]  Kris Zimmerman,et al.  CRISPR-Mediated Tagging of Endogenous Proteins with a Luminescent Peptide. , 2017, ACS chemical biology.

[21]  Heiner Koch,et al.  The target landscape of clinical kinase drugs , 2017, Science.

[22]  Jian Du,et al.  Preclinical characterization of abemaciclib in hormone receptor positive breast cancer , 2017, Oncotarget.

[23]  P. Workman,et al.  Inhibitors of cyclin‐dependent kinases as cancer therapeutics , 2017, Pharmacology & therapeutics.

[24]  Stephen J. Capuzzi,et al.  Progress towards a public chemogenomic set for protein kinases and a call for contributions , 2017, bioRxiv.

[25]  N. Gray,et al.  THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors , 2017, Nature Communications.

[26]  A. Burlingame,et al.  Broad-Spectrum Kinase Profiling in Live Cells with Lysine-Targeted Sulfonyl Fluoride Probes. , 2017, Journal of the American Chemical Society.

[27]  S. Chandarlapaty,et al.  Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence , 2016, Oncogene.

[28]  G. Vauquelin.  Effects of target binding kinetics on in vivo drug efficacy: koff, kon and rebinding , 2016, British journal of pharmacology.

[29]  R. Finn,et al.  Treating cancer with selective CDK4/6 inhibitors , 2016, Nature Reviews Clinical Oncology.

[30]  P. Lienau,et al.  Conformational Adaption May Explain the Slow Dissociation Kinetics of Roniciclib (BAY 1000394), a Type I CDK Inhibitor with Kinetic Selectivity for CDK2 and CDK9. , 2016, ACS chemical biology.

[31]  K. Bowman,et al.  Design and Development of a Series of Potent and Selective Type II Inhibitors of CDK8. , 2016, ACS medicinal chemistry letters.

[32]  Brock F. Binkowski,et al.  NanoLuc Complementation Reporter Optimized for Accurate Measurement of Protein Interactions in Cells. , 2016, ACS chemical biology.

[33]  M. Kinch,et al.  An analysis of FDA-approved drugs: natural products and their derivatives. , 2016, Drug discovery today.

[34]  Julian Blagg,et al.  Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19 , 2016, Journal of medicinal chemistry.

[35]  M. Clausen,et al.  Small-molecule kinase inhibitors: an analysis of FDA-approved drugs. , 2016, Drug discovery today.

[36]  K. Wood,et al.  Target engagement and drug residence time can be observed in living cells with BRET , 2015, Nature Communications.

[37]  Gary Box,et al.  A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease , 2015, Nature chemical biology.

[38]  Rosanne Raso,et al.  Changing a paradigm. , 2015, Nursing management.

[39]  L. Gelbert,et al.  Cyclin dependent kinase (CDK) inhibitors as anticancer drugs. , 2015, Bioorganic & medicinal chemistry letters.

[40]  C. Deane,et al.  Type II Inhibitors Targeting CDK2. , 2015, ACS chemical biology.

[41]  Peter J Tonge,et al.  Translating slow-binding inhibition kinetics into cellular and in vivo effects. , 2015, Nature chemical biology.

[42]  Leigh A. Stoddart,et al.  Application of BRET to monitor ligand binding to GPCRs , 2015, Nature Methods.

[43]  Agnieszka K. Witkiewicz,et al.  The history and future of targeting cyclin-dependent kinases in cancer therapy , 2015, Nature Reviews Drug Discovery.

[44]  K. Korn,et al.  A Novel CDK7 Inhibitor of the Pyrazolotriazine Class Exerts Broad-Spectrum Antiviral Activity at Nanomolar Concentrations , 2015, Antimicrobial Agents and Chemotherapy.

[45]  M. Drysdale,et al.  A novel small-molecule MRCK inhibitor blocks cancer cell invasion , 2014, Cell Communication and Signaling.

[46]  M. Malumbres,et al.  Cyclin-dependent kinases , 2014, Genome Biology.

[47]  Sridhar Ramaswamy,et al.  Targeting transcription regulation in cancer with a covalent CDK7 inhibitor , 2014, Nature.

[48]  Alastair J. King,et al.  Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors. , 2013, ACS medicinal chemistry letters.

[49]  S. Baumli,et al.  Perspective of Cyclin-dependent kinase 9 (CDK9) as a Drug Target , 2012, Current pharmaceutical design.

[50]  A. Futatsugi,et al.  Cyclin-dependent kinase 5 regulates E2F transcription factor through phosphorylation of Rb protein in neurons , 2012, Cell cycle.

[51]  Mindy I. Davis,et al.  Comprehensive analysis of kinase inhibitor selectivity , 2011, Nature Biotechnology.

[52]  G. Vauquelin.  Rebinding: or why drugs may act longer in vivo than expected from their in vitro target residence time , 2010, Expert opinion on drug discovery.

[53]  Li-Huei Tsai,et al.  Cyclin-dependent kinases: a family portrait , 2009, Nature Cell Biology.

[54]  J. Snyder,et al.  The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity. , 2009, Cancer research.

[55]  A. Tefferi,et al.  CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients , 2009, Leukemia.

[56]  M. Barbacid,et al.  Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.

[57]  J. Lyons,et al.  Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines , 2009, Molecular Cancer Therapeutics.

[58]  Pablo Tamayo,et al.  CDK8 is a colorectal cancer oncogene that regulates β-catenin activity , 2008, Nature.

[59]  Dwight M. Morrow,et al.  Discovery of novel and long acting muscarinic acetylcholine receptor antagonists. , 2008, Journal of medicinal chemistry.

[60]  Paul G Wyatt,et al.  Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design. , 2008, Journal of medicinal chemistry.

[61]  R. Copeland,et al.  Drug–target residence time and its implications for lead optimization , 2006, Nature Reviews Drug Discovery.

[62]  Kevan M Shokat,et al.  Features of selective kinase inhibitors. , 2005, Chemistry & biology.

[63]  N. Pryer,et al.  Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. , 2004, Molecular cancer therapeutics.

[64]  J. Biggs,et al.  Inhibitors of cyclin-dependent kinase and cancer , 1995, Journal of Molecular Medicine.

[65]  I. Iakovidis,et al.  The road ahead. , 2004, Studies in health technology and informatics.

[66]  R. Weinberg,et al.  The retinoblastoma protein and cell cycle control , 1995, Cell.

[67]  K. Johnson.  An Update. , 1984, Journal of food protection.